Combined Helicobacter pylori and FIT Screening: Cost-Effective Colorectal Cancer Prevention

In a randomized clinical trial-informed cost-effectiveness analysis, invitation to combined #Helicobacter #pylori stool #antigen testing and fecal immunochemical test (#FIT) screening for #colorectal #cancer was more effective and less costly than FIT alone under real-world adherence in Taiwan.

Co-testing reduced gastric cancer mortality and produced lifetime cost-savings per quality-adjusted life-year gained, with a benefit-cost ratio of over 5.

Sensitivity analyses identified H pylori prevalence as a dominant driver. In higher-cost settings, co-testing remained cost-effective when population H pylori prevalence exceeded 22%, supporting the strategy’s broader applicability.

https://ja.ma/4uIeGG6